Jurgis Strautmanis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jurgis Strautmanis has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Signe Setlere
European Reference Network EURO-NMD, 75013 Paris, France
2 shared publications - Baiba Lace
Latvian Biomedical Research and Study Centre, Riga, Latvia
1 shared publication - Daiga Murmane
From the Medical Genetics Clinic (B.L., I. Micule, G.T., D.M., I.G., O.S., I. Malniece), Children's Clinical University Hospital; Latvian Biomedical Research and Study Centre (B.L., J. Stavusis, D.L., D.K., I.I.); Rare Disease Centre (V.K.), Riga East Clinical University Hospital; Neurology Department (S.S., J. Strautmanis, I.K.), Children's Clinical University Hospital; Riga Maternity Hospital (L.K.); Riga Stradins University (Z.K.); Genera Ltd (I.R.-S., I.V.); and Scientific Laboratory of...
1 shared publication - Diana Livcane
From the Medical Genetics Clinic (B.L., I. Micule, G.T., D.M., I.G., O.S., I. Malniece), Children's Clinical University Hospital; Latvian Biomedical Research and Study Centre (B.L., J. Stavusis, D.L., D.K., I.I.); Rare Disease Centre (V.K.), Riga East Clinical University Hospital; Neurology Department (S.S., J. Strautmanis, I.K.), Children's Clinical University Hospital; Riga Maternity Hospital (L.K.); Riga Stradins University (Z.K.); Genera Ltd (I.R.-S., I.V.); and Scientific Laboratory of...
1 shared publication - Dita Kidere
From the Medical Genetics Clinic (B.L., I. Micule, G.T., D.M., I.G., O.S., I. Malniece), Children's Clinical University Hospital; Latvian Biomedical Research and Study Centre (B.L., J. Stavusis, D.L., D.K., I.I.); Rare Disease Centre (V.K.), Riga East Clinical University Hospital; Neurology Department (S.S., J. Strautmanis, I.K.), Children's Clinical University Hospital; Riga Maternity Hospital (L.K.); Riga Stradins University (Z.K.); Genera Ltd (I.R.-S., I.V.); and Scientific Laboratory of...
1 shared publication - Gita Taurina
Medical Genetics and Prenatal Diagnostic Clinic, Children's Clinical University Hospital, Riga, Latvia
1 shared publication
Latest Publications
- Open Access
- 11 December 2023
- Published by MDPI AG in Neurology International
- Vol. 15 (4) , 1489-1496
The Beneficial Outcome of Subsequent Treatment with Anakinra during the Chronic Phase of Febrile Infection-Related Epilepsy Syndrome (FIRES): A Case Report
This case report presents the clinical course of an eight-year-old boy diagnosed with febrile infection-related epilepsy syndrome (FIRES) at the age of four. Following a febrile infection, the patient experienced his initial episode of serial generalized clonic seizures. The severity of his condition led to 11 hospital admissions, totaling 157 days of hospitalization. Anakinra was initially administered during the acute phase in 2019 but was discontinued after 29 days. In 2022, the patient experienced a chronic-phase exacerbation and underwent a second course of anakinra treatment, which demonstrated a positive effect on seizure activity. With a year of anakinra therapy, the patient exhibited significant improvement in both seizure frequency and severity. This report adds to the existing evidence supporting the potential use of anakinra in the treatment of FIRES, highlighting its effectiveness during the chronic phase and suggesting the potential benefits of subsequent administration.
- 11 December 2023
- Published by MDPI AG in Neurology International
- Vol. 15 (4) , 1489-1496
Open AccessThe Beneficial Outcome of Subsequent Treatment with Anakinra during the Chronic Phase of Febrile Infection-Related Epilepsy Syndrome (FIRES): A Case Report
This case report presents the clinical course of an eight-year-old boy diagnosed with febrile infection-related epilepsy syndrome (FIRES) at the age of four. Following a febrile infection, the patient experienced his initial episode of serial generalized clonic seizures. The severity of his condition led to 11 hospital admissions, totaling 157 days of hospitalization. Anakinra was initially administered during the acute phase in 2019 but was discontinued after 29 days. In 2022, the patient experienced a chronic-phase exacerbation and underwent a second course of anakinra treatment, which demonstrated a positive effect on seizure activity. With a year of anakinra therapy, the patient exhibited significant improvement in both seizure frequency and severity. This report adds to the existing evidence supporting the potential use of anakinra in the treatment of FIRES, highlighting its effectiveness during the chronic phase and suggesting the potential benefits of subsequent administration.
- Open Access
- 16 May 2022
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 8 (3) , e685
Overview of Neuromuscular Disorder Molecular Diagnostic Experience for the Population of Latvia
Background and Objectives Genetic testing has become an integral part of health care, allowing the confirmation of thousands of hereditary diseases, including neuromuscular disorders (NMDs). The reported average prevalence of individual inherited NMDs is 3.7–4.99 per 10,000. This number varies greatly in the selected populations after applying population-wide studies. The aim of this study was to evaluate the effect of genetic analysis as the first-tier test in patients with NMD and to calculate the disease prevalence and allelic frequencies for reoccurring genetic variants. Methods Patients with NMD from Latvia with molecular tests confirming their diagnosis in 2008–2020 were included in this retrospective study. Results Diagnosis was confirmed in 153 unique cases of all persons tested. Next-generation sequencing resulted in a detection rate of 37%. Two of the most common childhood-onset NMDs in our population were spinal muscular atrophy and dystrophinopathies, with a birth prevalence of 1.01 per 10,000 newborns and 2.08 per 10,000 (male newborn population), respectively. The calculated point prevalence was 0.079 per 10,000 for facioscapulohumeral muscular dystrophy type 1, 0.078 per 10,000 for limb-girdle muscular dystrophy, 0.073 per 10,000 for nondystrophic congenital myotonia, 0.052 per 10,000 for spinobulbar muscular atrophy, and 0.047 per 10,000 for type 1 myotonic dystrophy. Discussion DNA diagnostics is a successful approach. The carrier frequencies of the common CAPN3, FKRP, SPG11, and HINT1 gene variants as well as that of the SMN1 gene exon 7 deletion in the population of Latvia are comparable with data from Europe. The carrier frequency of the CLCN1 gene variant c.2680C>T p.(Arg894Ter) is 2.11%, and consequently, congenital myotonia is the most frequent NMD in our population.
- 16 May 2022
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 8 (3) , e685
Open AccessOverview of Neuromuscular Disorder Molecular Diagnostic Experience for the Population of Latvia
Background and Objectives Genetic testing has become an integral part of health care, allowing the confirmation of thousands of hereditary diseases, including neuromuscular disorders (NMDs). The reported average prevalence of individual inherited NMDs is 3.7–4.99 per 10,000. This number varies greatly in the selected populations after applying population-wide studies. The aim of this study was to evaluate the effect of genetic analysis as the first-tier test in patients with NMD and to calculate the disease prevalence and allelic frequencies for reoccurring genetic variants. Methods Patients with NMD from Latvia with molecular tests confirming their diagnosis in 2008–2020 were included in this retrospective study. Results Diagnosis was confirmed in 153 unique cases of all persons tested. Next-generation sequencing resulted in a detection rate of 37%. Two of the most common childhood-onset NMDs in our population were spinal muscular atrophy and dystrophinopathies, with a birth prevalence of 1.01 per 10,000 newborns and 2.08 per 10,000 (male newborn population), respectively. The calculated point prevalence was 0.079 per 10,000 for facioscapulohumeral muscular dystrophy type 1, 0.078 per 10,000 for limb-girdle muscular dystrophy, 0.073 per 10,000 for nondystrophic congenital myotonia, 0.052 per 10,000 for spinobulbar muscular atrophy, and 0.047 per 10,000 for type 1 myotonic dystrophy. Discussion DNA diagnostics is a successful approach. The carrier frequencies of the common CAPN3, FKRP, SPG11, and HINT1 gene variants as well as that of the SMN1 gene exon 7 deletion in the population of Latvia are comparable with data from Europe. The carrier frequency of the CLCN1 gene variant c.2680C>T p.(Arg894Ter) is 2.11%, and consequently, congenital myotonia is the most frequent NMD in our population.